Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: May 14, 2025
Reporting Period: Quarter ended March 31, 2025
Context: This filing serves as a notification that the company issued a press release on May 14, 2025, announcing its financial results for the quarter ended March 31, 2025. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text acts as a cover document and does not contain specific financial data points. The filing explicitly states that the detailed results are contained within the attached press release (Exhibit 99.1), which is not included in the input text. Therefore, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes versus the prior comparable period are described in the text of this Form 8-K. The document only references the issuance of the press release containing the results.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. These items, if present, are located within the referenced Exhibit 99.1 press release.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) for actual revenue, net loss, and cash position figures for the quarter ended March 31, 2025.
- Verify the company's cash runway and burn rate, as these are critical for a pre-revenue or early-stage biotech firm like BioCardia.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm if there were any changes in capital structure or financing activities during the quarter.